Literature DB >> 23846335

[Inhalative loxapine: old tried and trusted medication with new indications].

G Juckel1.   

Abstract

Inhalative loxapine which will come onto the market shortly, is an important new alternative medication for the treatment of agitation, restlessness and tension in patients with schizophrenia and bipolar disorders. The possibility of inhaled administration provides an advantage for patients and staff in certain acute situations. In patients with obstructive lung diseases there is a danger concerning bronchospasms. The resulting safety regulations limit the easy and broad usage of inhaled loxapine slightly but these can be easily realized within hospitals. In view of the rapid onset antiagitation effect and the easy handling of inhaled loxapine, this might be a rather minor problem.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23846335     DOI: 10.1007/s00115-013-3840-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  11 in total

1.  [A new evidence and consensus-based German guidelines for diagnosis and treatment of bipolar disorders].

Authors:  M Bauer
Journal:  Nervenarzt       Date:  2012-05       Impact factor: 1.214

2.  In vitro aerosol characterization of Staccato(®) Loxapine.

Authors:  Khe Dinh; Dan J Myers; Marc Glazer; Tamara Shmidt; Caitlin Devereaux; Kathleen Simis; Peter D Noymer; Min He; Corinna Choosakul; Qiang Chen; James V Cassella
Journal:  Int J Pharm       Date:  2010-10-31       Impact factor: 5.875

Review 3.  Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-03       Impact factor: 9.546

4.  Contrasting loxapine to its isomer isoloxapine--the critical role of in vivo D2 blockade in determining atypicality.

Authors:  Sridhar Natesan; Suzi Vanderspek; José N Nobrega; Robert A McClelland; Shitij Kapur
Journal:  Schizophr Res       Date:  2005-09-15       Impact factor: 4.939

5.  Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial.

Authors:  Michael H Allen; David Feifel; Michael D Lesem; Daniel L Zimbroff; Ruth Ross; Patrik Munzar; Daniel A Spyker; James V Cassella
Journal:  J Clin Psychiatry       Date:  2011-10       Impact factor: 4.384

Review 6.  Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.

Authors:  L Citrome
Journal:  Int J Clin Pract       Date:  2012-01-09       Impact factor: 2.503

7.  Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine.

Authors:  Joseph Kwentus; Robert A Riesenberg; Morteza Marandi; Raymond A Manning; Michael H Allen; Robert S Fishman; Daniel A Spyker; John H Kehne; James V Cassella
Journal:  Bipolar Disord       Date:  2012-02       Impact factor: 6.744

Review 8.  Loxapine for schizophrenia.

Authors:  A Chakrabarti; A Bagnall; P Chue; M Fenton; V Palaniswamy; W Wong; J Xia
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

9.  Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers.

Authors:  Daniel A Spyker; Patrik Munzar; James V Cassella
Journal:  J Clin Pharmacol       Date:  2009-11-13       Impact factor: 3.126

10.  [S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations].

Authors:  A Pfennig; T Bschor; T Baghai; P Bräunig; P Brieger; P Falkai; D Geissler; R Gielen; H Giesler; O Gruber; I Kopp; T D Meyer; K H Möhrmann; C Muche-Borowski; F Padberg; H Scherk; D Strech; M Bauer
Journal:  Nervenarzt       Date:  2012-05       Impact factor: 1.214

View more
  2 in total

1.  [Inhaled loxapine for emergency treatment of agitated patients with borderline personality disorder : A series of five cases].

Authors:  T H C Krüger; M A Wollmer; P Negt; H Frieling; S Jung; K G Kahl
Journal:  Nervenarzt       Date:  2016-11       Impact factor: 1.214

Review 2.  [Acute agitation conditions].

Authors:  P Mavrogiorgou; G Juckel
Journal:  Nervenarzt       Date:  2015-09       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.